Patient Search

KaCrole Higgins was diagnosed with breast cancer in 2020. “In May 2020, I found a lump in my breast. I cried. By June, it was diagnosed as breast cancer, triple positive, stage 1A. While getting this cancer diagnosis was devastating, it also became an opportunity. Suddenly, the cancer gave me clarity. It gave me clarity about what was important, what was good in my life, what was toxic in my life, and what I needed to do.” Click below to read more of KaCrole’s story

https://momentum.vicc.org/2022/04/cancer-gave-me-clarity/

If Landon Ryan had been diagnosed with bilateral retinoblastoma 10, 20 or 30 years ago, she might not be here today with nearly perfect vision.Thanks to recent improvements in the treatment for this rare form of cancer that almost exclusively affects children under the age of 5, the diagnosis had the power to change Landon’s life when she was 11 months old, but not to take it — or her eyesight. Click below to learn more about Landon and her story.

https://momentum.vicc.org/2022/04/brighter-outlook/

Filter By:
Search by Keyword:

Displaying 1 - 10 of 23

Clamping Down the Metabolic Pipeline to B Cells

New research shows the nutritive needs of B cells are more flexible than previously thought, which could enable researchers to steer antibody production in the lymph nodes and spleen to better combat autoimmunity. Patients with high-risk diseases of the immune system, particularly systemic lupus erythematosus, could stand to benefit from the research findings. The study led by Mark Boothby, MD, and published in the Journal of Immunology, provides details regarding how murine B cells use different sugars as they mature into antibody-producing cells

https://discoveries.vanderbilthealth.com/2024/02/clamping-down-the-metabolic-pipeline-to-b-cells/

Wed, 02/28/2024 - 12:00

Host-Tumor_Interactions_Research_Program

Vanderbilt Health

Locked

Colorectal cancer 'cartography' reveals an avenue to improved immunotherapy

Vanderbilt University Medical Center researchers have discovered why most colorectal tumors escape detection and destruction by the body's immune system.

https://news.vumc.org/2023/12/11/colorectal-cancer-cartography-reveals-an-avenue-to-improved-immunotherapy/

Mon, 12/11/2023 - 12:00

Gastrointestinal_Cancer_Research_Program

Bill Snyder

Locked

VUMC researchers upend dogma about vasopressin production

Vanderbilt investigators have discovered that vasopressin, which has long been thought to be produced only in the brain, is also produced in the kidney.

https://news.vumc.org/2023/01/05/study-upends-dogma-vasopressin-production/

Thu, 01/05/2023 - 12:00

Cancer_Cell_Biology_Research_Program

Translational_Research_and_Interventional_Oncology_Research_Program

Leigh MacMillan

Locked

Please s

Multiple Cancer Types

This phase I trial tests the safety, side effects, and best dose of eltanexor in combination with venetoclax for the treatment of patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Eltanexor works by trapping "tumor suppressing proteins" within the cell, thus causing the cancer cells to die or stop growing. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving eltanexor together with venetoclax may be safe, tolerable and/or effective in treating patients with relapsed or refractory MDS or AML.

Disease Sites: Leukemia, Myelodysplastic Syndrome, Phase I

Phase: I

Investigator: Ball, Somedeb

NCTID: NCT06399640

Protocol No: VICC-VCHEM23008P

Learn More

Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers

Multiple Cancer Types

This phase I trial tests the safety, side effects, and best dose of ZEN003694 in combination with the usual treatment with capecitabine in treating patients with cancer that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot be removed by surgery (unresectable) and that it has progressed on previous standard treatment. ZEN003694 is an inhibitor of a family of proteins called the bromodomain and extra-terminal (BET). It may prevent the growth of tumor cells that over produce BET protein. Capecitabine is in a class of medications called antimetabolites. It is taken up by cancer cells and breaks down into fluorouracil, a substance that kills cancer cells. Giving ZEN003694 in combination with capecitabine may be safe in treating patients with metastatic or unresectable solid tumors.

Disease Sites: Colon, Phase I, Rectal

Phase: I

Investigator: Heumann, Thatcher

NCTID: NCT05803382

Protocol No: VICC-NTPHI23420

Learn More

A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With HR+ Breast Cancer and Other Select Solid Tumors

Multiple Cancer Types

The goal of this clinical trial is to evaluate the safety of TOS-358 in adults with select solid tumors who meet study enrollment criteria. The main questions it aims to answer are:

1. what is the maximum tolerated dose and recommended dose for phase 2?
2. how safe and tolerable is TOS-358 at different dose levels when taken orally once or twice per day?

Disease Sites: Breast, Cervical, Gastrointestinal, Gynecologic, Head/Neck, Lung, Phase I, Urologic

Phase: I

Investigator: Berlin, Jordan

NCTID: NCT05683418

Protocol No: VICC-DTPHI23103

Learn More

Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors

Phase I

RBS2418 (investigational product) is a specific immune modulator, working through ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1), designed to lead to anti-tumor immunity by increasing endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) and adenosine triphosphate (ATP levels) and reducing adenosine production in the tumors. RBS2418 has the potential to be an important therapeutic option for subjects both as monotherapy and in combination with other cancer treatments including monotherapy and in combination with other cancer treatments including immunotherapy or chemotherapy. This study is an open-label, multi-site Phase 1a/1b study of RBS2418, a selective ENPP1 inhibitor, in combination with pembrolizumab or other approved anticancer therapies or as a monotherapy in subjects with advanced unresectable, recurrent or metastatic tumors. The phase 1a (dose escalation phase) has been completed. The Phase 1b expansion phase of the study has been increased in size and scope.

Disease Sites: Phase I

Phase: I

Investigator: Berlin, Jordan

NCTID: NCT05270213

Protocol No: VICCPHI2289

Learn More

Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma

Multiple Cancer Types

The purpose of the study is to evaluate the safety and survival of carmustine wafers and radiation and retifanlimab with or without temozolomide (TMZ) in newly-diagnosed adult subjects with glioblastoma multiform after carmustine wafer placement.

Disease Sites: Neuro-Oncology, Phase I

Phase: I

Investigator: Thompson, Reid

NCTID: NCT05083754

Protocol No: VICCNEUP22119

Learn More